Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07454642 · ClinicalTrials.gov registry record · Phase 1
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
A Phase 1 study of Gastric Adenocarcinoma and Cervical Adenocarcinoma, sponsored by Avacta Life Sciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 144
- Enrollment target
- 2
- Study locations
NCT07454642 is a Phase 1 study of Gastric Adenocarcinoma and Cervical Adenocarcinoma that is actively recruiting participants, run by Avacta Life Sciences. The registered enrollment target is 144 participants, below the 242-participant average among 47 other Gastric Adenocarcinoma trials with a reported enrollment target (40% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT07454642, a Phase 1 study of Gastric Adenocarcinoma and Cervical Adenocarcinoma, is actively recruiting participants, sponsored by Avacta Life Sciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 144 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a first-in-human (FIH), Phase 1 open-label, multicenter dose escalation study investigating AVA6103 monotherapy administered intravenously in patients with locally advanced (unresectable) or metastatic solid tumors that are likely to be FAP positive. The study consists of an initial Phase 1a dose escalation portion and a subsequent Phase 1b dose expansion portion upon completion of the dose escalation portion.
Conditions Studied
Interventions
- DRUG AVA6103
Study Locations (2)
Texas
- NEXT Oncology - Irving
Virginia
- NEXT Oncology Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2026-03 |
| Est. Completion | 2030-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07454642
The ClinicalTrials.gov registry entry for NCT07454642 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 47 other Gastric Adenocarcinoma trials with a reported enrollment target (40% lower). The listed sponsor is Avacta Life Sciences, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Gastric Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which AVA6103 is the first listed.
NCT07454642 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Texas, Virginia.
Frequently Asked Questions
What is clinical trial NCT07454642 about?
NCT07454642 is a clinical study titled "AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors". This is a first-in-human (FIH), Phase 1 open-label, multicenter dose escalation study investigating AVA6103 monotherapy administered intravenously in patients with locally advanced (unresectable) or metastatic solid tumors that are likely to be FAP positive. The study consists of an initial Phase 1a...
What is the current status of trial NCT07454642?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 144 participants. The study started on 2026-03. Estimated completion is 2030-06.
What conditions does trial NCT07454642 study?
This clinical trial studies the following conditions: Gastric Adenocarcinoma, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, GEJ Adenocarcinoma.
What interventions are being tested in trial NCT07454642?
The interventions under investigation include: AVA6103 (DRUG).
Who is sponsoring clinical trial NCT07454642?
This trial is sponsored by Avacta Life Sciences, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07454642 being conducted?
This trial has 2 study locations across Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
RECRUITING · Phase 1
-
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
RECRUITING · Phase 1
-
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.